Is Solid Biosciences Inc. (SLDB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 4.6% / 30% | 28.3% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 4.6% / 33% | 28.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 12.8% / 33% | 78.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 4.6% / 33% | 28.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 12.8% / 33% | 78.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -109.9% | |
| Return on Assets (ROA) | -53.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$100M |
| Free Cash Flow | -$101M |
| Total Debt | $24M |
| Debt-to-Equity | 11.8 |
| Current Ratio | 6.1 |
| Total Assets | $189M |
Price & Trading
| Last Close | $7.73 |
| 50-Day MA | $6.59 |
| 200-Day MA | $5.80 |
| Avg Volume | 1.3M |
| Beta | 2.8 |
|
52-Week Range
$2.41
| |
About Solid Biosciences Inc. (SLDB)
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Solid Biosciences Inc. (SLDB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Solid Biosciences Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Solid Biosciences Inc.'s debt ratio?
Solid Biosciences Inc.'s debt ratio is 4.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.8%.
What are Solid Biosciences Inc.'s key financial metrics?
Solid Biosciences Inc. has a market capitalization of $700M. Return on equity stands at -109.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.